{"filing":{"accession_number":"0001493152-26-035013","cik":"0001847846","ticker":"EUDAW","company_name":"EUDA Health Holdings Ltd","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"form6-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1847846/000149315226035013/form6-k.htm"},"events":[{"id":21144,"run_id":19059,"accession_number":"0001493152-26-035013","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"EUDA Health announced a tri-party Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on development, manufacturing, and commercialization of next-generation iPSC and NK-TCR cell therapies for oncology. This is a material strategic partnership and product development milestone that aligns with the company's stated strategy to strengthen commercialization capabilities in innovative healthcare products. While not a binding acquisition or debt issuance, the MOU represents a significant operational and strategic business development event that would affect a reasonable investor's assessment of the company's growth prospects and product pipeline.","company_name":"EUDA Health Holdings Ltd","ticker":"EUDAW","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":[{"id":20703,"accession_number":"0001493152-26-035013","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"EUDA Health announced a tri-party Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on development, manufacturing, and commercialization of next-generation iPSC and NK-TCR cell therapies for oncology. This is a material strategic partnership and product development milestone that aligns with the company's stated strategy to strengthen commercialization capabilities in innovative healthcare products. While not a binding acquisition or debt issuance, the MOU represents a significant operational and strategic business development event that would affect a reasonable investor's assessment of the company's growth prospects and product pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:31:51.524598+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20703,"accession_number":"0001493152-26-035013","item_number":"EX-99.1","item_title":"ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"EUDA Health announced a tri-party Memorandum of Understanding with GO POSB Organoids and Shenzhen Innovation Immunotechnology to collaborate on development, manufacturing, and commercialization of next-generation iPSC and NK-TCR cell therapies for oncology. This is a material strategic partnership and product development milestone that aligns with the company's stated strategy to strengthen commercialization capabilities in innovative healthcare products. While not a binding acquisition or debt issuance, the MOU represents a significant operational and strategic business development event that would affect a reasonable investor's assessment of the company's growth prospects and product pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-28T20:31:51.524598+00:00","company_name":"EUDA Health Holdings Ltd","ticker":"EUDAW","filing_date":"2026-07-28"}]}